Life Glow Plus
Super Life Glow
Life Glow Basic
Bone Dense Calcium
Taheebo Life Tea
Germanium
Colloidal Minerals
Methyl Sulfonyl Methane
Transfer Factor
Immune Egg

Vibrant Life Home Web
All VL Products
Family Of Three Chelation Formulas
Oral Chelation Ingredient Comparisons

The Wednesday Letter
Karl Loren Viewpoints
Frequently Asked Questions
Testimonials

Free Radicals
Central Page For 18 Web Sites
Vibrant Life Home Page

Shopping Cart

Separate Search Page
or search below


Navigation Help

Karl Loren Background

Ingredients Technical Write To Karl Loren Table Of Contents

l Carnitine

Research Studies

 


Results for your query:
Words in title only: Carnitine
Published in 1957 through 1999
Only select references with abstracts available
Show references published in English only
Show references pertaining to humans
With an article type of: REVIEW

Documents: 1 to 50 of 94

1 Mitchell ME; Carnitine metabolism in human subjects. II. Values of carnitine in biological fluids and tissues of "normal" subjects. (Am J Clin Nutr, 1978 Mar, Abstract available) [MEDLINE]
2 Krähenbühl S; Carnitine metabolism in chronic liver disease. (Life Sci, 1996, Abstract available) [MEDLINE]
3 Giovannini M, et al; Is carnitine essential in children? (J Int Med Res, 1991 Mar, Abstract available) [MEDLINE]
4 Tein I, et al; Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitine-responsive cardiomyopathy. (Pediatr Res, 1990 Sep, Abstract available) [MEDLINE]
5 Jeulin C, et al; Role of free L-carnitine and acetyl-L-carnitine in post-gonadal maturation of mammalian spermatozoa. (Hum Reprod Update, 1996 Mar, Abstract available) [MEDLINE]
6 Mitchell ME; Carnitine metabolism in human subjects. I. Normal metabolism. (Am J Clin Nutr, 1978 Feb, Abstract available) [MEDLINE]
7 Mitchell ME; Carnitine metabolism in human subjects. III. Metabolism in disease. (Am J Clin Nutr, 1978 Apr, Abstract available) [MEDLINE]
8 Brass EP, et al; The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs [see comments] (J Am Coll Nutr, 1998 Jun, Abstract available) [MEDLINE]
9 Tanphaichitr V, et al; Carnitine metabolism and human carnitine deficiency. (Nutrition, 1993 May, Abstract available) [MEDLINE]
10 Kanter MM, et al; Antioxidants, carnitine, and choline as putative ergogenic aids. (Int J Sport Nutr, 1995 Jun, Abstract available) [MEDLINE]

Menu Position #10

11 Na…ecz KA, et al; Carnitine--a known compound, a novel function in neural cells. (Acta Neurobiol Exp (Warsz), 1996, Abstract available) [MEDLINE]
12 Faigel HC; Carnitine palmitoyltransferase deficiency in a college athlete: a case report and literature review. (J Am Coll Health, 1995 Sep, Abstract available) [MEDLINE]
13 McGarry JD, et al; New insights into the mitochondrial carnitine palmitoyltransferase enzyme system. (Biochimie, 1991 Jan, Abstract available) [MEDLINE]
14 Berard E, et al; L-carnitine in dialysed patients: the choice of dosage regimen. (Int J Clin Pharmacol Res, 1995, Abstract available) [MEDLINE]
15 McCarty MF, et al; Pyruvate and hydroxycitrate/carnitine may synergize to promote reverse electron transport in hepatocyte mitochondria, effectively 'uncoupling' the oxidation of fatty acids. (Med Hypotheses, 1999 May, Abstract available) [MEDLINE]
16 Novak M; Carnitine supplementation in soy-based formula-fed infants. (Biol Neonate, 1990, Abstract available) [MEDLINE]
17 Pons R, et al; Primary and secondary carnitine deficiency syndromes. (J Child Neurol, 1995 Nov, Abstract available) [MEDLINE]
18 Mintz M; Carnitine in human immunodeficiency virus type 1 infection/acquired immune deficiency syndrome. (J Child Neurol, 1995 Nov, Abstract available) [MEDLINE]
19 Coulter DL; Carnitine deficiency in epilepsy: Risk factors and treatment. (J Child Neurol, 1995 Nov, Abstract available) [MEDLINE]
20 Carter AL, et al; Biosynthesis and metabolism of carnitine. (J Child Neurol, 1995 Nov, Abstract available) [MEDLINE]

Menu Position #20

21 Borum PR; Carnitine in neonatal nutrition. (J Child Neurol, 1995 Nov, Abstract available) [MEDLINE]
22 Cook GA, et al; Expression and regulation of carnitine palmitoyltransferase-Ialpha and -Ibeta genes. (Am J Med Sci, 1999 Jul, Abstract available) [MEDLINE]
23 Ramsay RR; The role of the carnitine system in peroxisomal fatty acid oxidation. (Am J Med Sci, 1999 Jul, Abstract available) [MEDLINE]
24 Pande SV; Carnitine-acylcarnitine translocase deficiency. (Am J Med Sci, 1999 Jul, Abstract available) [MEDLINE]
25 Scaglia F, et al; Primary and secondary alterations of neonatal carnitine metabolism. (Semin Perinatol, 1999 Apr, Abstract available) [MEDLINE]
26 Williamson JR, et al; The roles of glucose-induced metabolic hypoxia and imbalances in carnitine metabolism in mediating diabetes-induced vascular dysfunction. (Int J Clin Pharmacol Res, 1992, Abstract available) [MEDLINE]
27 Angelini C, et al; Clinical and biochemical aspects of carnitine deficiency and insufficiency: transport defects and inborn errors of beta-oxidation. (Crit Rev Clin Lab Sci, 1992, Abstract available) [MEDLINE]
28 Arenas J, et al; Biological roles of L-carnitine in perinatal metabolism. (Early Hum Dev, 1998 Dec, Abstract available) [MEDLINE]
29 Brass EP; Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. (Clin Ther, 1995 Mar, Abstract available) [MEDLINE]
30 Rebouche CJ; Carnitine function and requirements during the life cycle. (FASEB J, 1992 Dec, Abstract available) [MEDLINE]

Menu Position #30

31 Anderson RC; Carnitine palmitoyltransferase: a viable target for the treatment of NIDDM? (Curr Pharm Des, 1998 Feb, Abstract available) [MEDLINE]
32 Igisu H, et al; Protection of the brain by carnitine. (Sangyo Eiseigaku Zasshi, 1995 Mar, Abstract available) [MEDLINE]
33 Pierce MR, et al; Fatal carnitine palmitoyltransferase II deficiency in a newborn: new phenotypic features. (Clin Pediatr (Phila), 1999 Jan, Abstract available) [MEDLINE]
34 Bergman AJ, et al; Rate-dependent distal renal tubular acidosis and carnitine palmitoyltransferase I deficiency. (Pediatr Res, 1994 Nov, Abstract available) [MEDLINE]
35 Sugden MC, et al; Interactive regulation of the pyruvate dehydrogenase complex and the carnitine palmitoyltransferase system. (FASEB J, 1994 Jan, Abstract available) [MEDLINE]
36 Felipo V, et al; Molecular mechanism of acute ammonia toxicity and of its prevention by L-carnitine. (Adv Exp Med Biol, 1994, Abstract available) [MEDLINE]
37 Kelly GS; L-Carnitine: therapeutic applications of a conditionally-essential amino acid. (Altern Med Rev, 1998 Oct, Abstract available) [MEDLINE]
38 Rebouche CJ, et al; Carnitine metabolism and its regulation in microorganisms and mammals. (Annu Rev Nutr, 1998, Abstract available) [MEDLINE]
39 Kerner J, et al; Genetic disorders of carnitine metabolism and their nutritional management. (Annu Rev Nutr, 1998, Abstract available) [MEDLINE]
40 Hülsmann WC, et al; Carnitine and cardiac interstitium. (Cardioscience, 1994 Jun, Abstract available) [MEDLINE]

Menu Position #40

41 Stanley CA, et al; Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake. (Ann Neurol, 1991 Nov, Abstract available) [MEDLINE]
42 Rebouche CJ; Ascorbic acid and carnitine biosynthesis. (Am J Clin Nutr, 1991 Dec, Abstract available) [MEDLINE]
43 A role for carnitine in medium-chain fatty acid metabolism? (Nutr Rev, 1991 Aug, Abstract available) [MEDLINE]
44 Paulson DJ; Carnitine deficiency-induced cardiomyopathy. (Mol Cell Biochem, 1998 Mar, Abstract available) [MEDLINE]
45 Park EA, et al; Differential regulation in the heart of mitochondrial carnitine palmitoyltransferase-I muscle and liver isoforms. (Mol Cell Biochem, 1998 Mar, Abstract available) [MEDLINE]
46 Wiseman LR, et al; Propionyl-L-carnitine. (Drugs Aging, 1998 Mar, Abstract available) [MEDLINE]
47 Brass EP, et al; Carnitine metabolism during exercise. (Life Sci, 1994, Abstract available) [MEDLINE]
48 Marzo A, et al; L-Carnitine moiety assay: an up-to-date reappraisal covering the commonest methods for various applications. (J Chromatogr B Biomed Sci Appl, 1997 Nov, Abstract available) [MEDLINE]
49 Carta A, et al; Acetyl-L-carnitine and Alzheimer's disease: pharmacological considerations beyond the cholinergic sphere. (Ann N Y Acad Sci, 1993 Sep, Abstract available) [MEDLINE]
50 Brady PS, et al; Regulation of the long-chain carnitine acyltransferases. (FASEB J, 1993 Aug, Abstract available) [MEDLINE]



-------------- -------------- --------------

 


Record 1 from database: MEDLINE
Return To Top

Title
Carnitine metabolism in human subjects. II. Values of carnitine in biological fluids and tissues of "normal" subjects.
Author
Mitchell ME
Address
 
Source
Am J Clin Nutr, 1978 Mar, 31:3, 481-91
Abstract
Carnitine values in "normal" or "control" human subjects are assembled in the second part of this review. Data were found on blood, skeletal muscle, urine, heart muscle, and semen. Factors that affect these measures are related to the data.
Language of Publication
English
Unique Identifier
78121101

Return To Top


MeSH Heading (Major)
Carnitine|BL/*ME/UR
MeSH Heading
Adolescence; Adult; Aged; Aging; Child; Diet; Exertion; Fasting; Female; Human; Male; Menstruation; Middle Age; Muscles|ME; Reference Values; Sex Factors

Publication Type
JOURNAL ARTICLE; REVIEW
ISSN
0002-9165
Country of Publication
UNITED STATES

Record 2 from database: MEDLINE
Return To Top

Title
Carnitine metabolism in chronic liver disease.
Author
Krähenbühl S
Address
Department of Internal Medicine, University Hospital, Zurich, Switzerland.
Source
Life Sci, 1996, 59:19, 1579-99
Abstract
The liver is a central organ for carnitine metabolism and for the distribution of carnitine to the body. It is therefore not surprising that carnitine metabolism is impaired in patients and experimental animals with certain types of chronic liver disease. In this review, the changes in carnitine metabolism associated with chronic liver disease and the role of carnitine as a therapeutic agent in some of these conditions are discussed.
Language of Publication
English
Unique Identifier
97070398

Return To Top


MeSH Heading (Major)
Carnitine|*ME/TU; Fatty Liver|CO/*ME; Liver Cirrhosis|CI/DT/ET/*ME
MeSH Heading
Animal; Chronic Disease; Fatty Liver, Alcoholic|ME; Hepatitis, Viral, Human|CO; Human; Liver Cirrhosis, Alcoholic|ME; Liver Cirrhosis, Biliary|ME; Support, Non-U.S. Gov't

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0024-3205
Country of Publication
ENGLAND

Record 3 from database: MEDLINE
Return To Top

Title
Is carnitine essential in children?
Author
Giovannini M; Agostoni C; Salari PC
Address
Fifth Department of Paediatrics, University of Milan, Italy.
Source
J Int Med Res, 1991 Mar, 19:2, 88-102
Abstract
Carnitine has a fundamental biological role as a long-chain fatty acid carrier across the mitochondrial membrane and in ketone body formation. Although the body normally synthesizes carnitine, in certain circumstances such as total parenteral nutrition and haemodialysis a dietary supplement may be needed to maintain adequate levels. Several considerations suggest that carnitine is a truly essential nutrient in infancy and in other situations where the energy requirement is particularly high, e.g. pregnancy and breast feeding. There are, for example, congenital deficit syndromes due to enzymatic inadequacies. There is also the possible role of carnitine in serious metabolic disorders such as organic acidaemias and, above all, it has multiple physiological functions in major metabolic pathways which are essential for development and growth.
Language of Publication
English
Unique Identifier
91323648

Return To Top


MeSH Heading (Major)
Carnitine|DF/*ME/TU
MeSH Heading
Animal; Comparative Study; Female; Human; Infant; Infant, Newborn; Kidney|ME; Liver|ME; Metabolism, Inborn Errors|PP; Milk, Human|CH; Nutritional Requirements; Pregnancy; Rats

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0300-0605
Country of Publication
ENGLAND

Record 4 from database: MEDLINE
Return To Top

Title
Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitine-responsive cardiomyopathy.
Author
Tein I; De Vivo DC; Bierman F; Pulver P; De Meirleir LJ; Cvitanovic Sojat L; Pagon RA; Bertini E; Dionisi Vici C; Servidei S; et al
Address
Division of Pediatric Neurology, Columbia University, New York, New York 10032.
Source
Pediatr Res, 1990 Sep, 28:3, 247-55
Abstract
Evidence is emerging that primary systemic carnitine deficiency, a potentially lethal but eminently treatable inborn error of fatty acid oxidation, involves a cellular defect in the uptake of carnitine. We present four unrelated children with primary carnitine-responsive cardiomyopathy, weakness (with or without hypoketotic hypoglycemic encephalopathy), low serum and/or tissue carnitine concentrations, and severe renal carnitine leak. Dicarboxylic acids were absent in the urine of three children who were tested, and all four had a rapid and dramatic improvement in cardiac function, strength, and somatic growth after carnitine therapy. We studied carnitine uptake in cultured skin fibroblasts from all four children and seven of the eight healthy nonconsanguinous parents. [3H]L-carnitine uptake was evaluated in vitro under linear time kinetics. Substrate concentrations were varied from 0.1 to 1000 microM. Physiologic uptake was determined at carnitine concentrations between 0.1 and 50 microM. Nonspecific uptake was determined at a concentration of 10 mM. The four patients had negligible uptake throughout the physiologic range, implying a marked deficiency in the specific high-affinity, low-concentration, carrier-mediated uptake mechanism. At a concentration of 5 mumol/L, the mean velocity of uptake in the four patients was 2% of control values. Their parents showed intermediate maximal rates of carnitine uptake ranging from 13 to 44% of control Vmax values, but normal Km values, suggesting that the heterozygotes had a reduced number of normal functioning carnitine transporters. The observed reduction in Vmax values for the parents supports an autosomal recessive inheritance pattern and may be a more sensitive indicator of heterozygosity than serum carnitine concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)
Language of Publication
English
Unique Identifier
91044610

Return To Top


MeSH Heading (Major)
Carnitine|*DF/ME/TU; Lipid Metabolism, Inborn Errors|CO/DT/*ME; Myocardial Diseases|DT/ET/*ME
MeSH Heading
Biological Transport, Active; Case Report; Child; Child, Preschool; Fatty Acids|ME; Female; Fibroblasts|ME; Human; Male; Skin|ME; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0031-3998
Country of Publication
UNITED STATES

Record 5 from database: MEDLINE
Return To Top

Title
Role of free L-carnitine and acetyl-L-carnitine in post-gonadal maturation of mammalian spermatozoa.
Author
Jeulin C; Lewin LM
Address
Laboratoire de Biologie de la Reproduction et du DÆeveloppment, Centre Hospitalier Universitaire, Le Kremlin-BicÈetre, France.
Source
Hum Reprod Update, 1996 Mar, 2:2, 87-102
Abstract
Spermatozoa are produced in the testis and undergo post-gonadal modifications in the epididymis to acquire fertilizing ability. In epididymal plasma, high-molecular-weight proteins and such small molecules as free-L carnitine convert the gametes into "competent' and functional cells. This review summarizes the knowledge pertaining to L-carnitine and the significance of free L-carnitine uptake into the mature spermatozoa of mammals. We provide an overview of the function of free L-carnitine and carnitine esters in the metabolism of eukaryotic cells and review the role of the specific carnitine acyltransferases in mitochondrial transport of fatty acids and in modulating acyl-coenzyme A (CoA) pools in cellular organelles. In mammals, including man, free L-carnitine is taken from blood plasma and concentrated in the epididymal lumen. This epididymal secretion is beneficial for spermatozoa and is not merely an excretory waste. The uptake of free L-carnitine into the spermatozoa and its metabolic outcome are discussed first in in-vivo and then in in-vitro situations. Free L-carnitine goes through the sperm plasma membrane by passive diffusion. Free L-carnitine is acetylated in mature spermatozoa only. The excess acetyl-CoA from the mitochondria is probably stored as acetyl-L-carnitine and modulates the reserves of free CoA essential to the function of the tricarboxylic acid cycle. These properties of L-carnitine of buffering CoA in the mitochondrial matrix are known in somatic cells but are accentuated in this study of the male germinal cells. In the future, a precise measurement of the in-vivo and in-vitro concentrations of free CoA and acetyl-CoA in the cellular compartments of immature and mature spermatozoa might complete these data. The relationship between the endogenous pools of free and acetylated L-carnitine and the percentage of progressive sperm motility indicates a more important metabolic function related to flagellar movement. In conclusion, the potential to initiate sperm motility, which takes place in the epididymis, is probably independent of the carnitine system, while the energy properties of acetyl-L-carnitine can only be relevant in situations of "energy crisis'. The uptake of "cytoplasmic' free L-carnitine in mature spermatozoa must be a protective form of mitochondrial metabolism, useful to the survival of this isolated cell.
Language of Publication
English
Unique Identifier
97233217

Return To Top


MeSH Heading (Major)
Acetylcarnitine|*ME; Carnitine|*ME; Carnitine Acyltransferases|*ME; Sperm Maturation|*PH
MeSH Heading
Animal; Ejaculation; Epididymis|ME; Epithelium|ME; Human; Male; Semen|ME; Sperm Motility; Support, Non-U.S. Gov't

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
1355-4786
Country of Publication
ENGLAND

Record 6 from database: MEDLINE
Return To Top

Title
Carnitine metabolism in human subjects. I. Normal metabolism.
Author
Mitchell ME
Address
 
Source
Am J Clin Nutr, 1978 Feb, 31:2, 293-306
Abstract
Carnitine (vitamin BT) is a compound which is involved with lipid metabolism. This article deals with the carnitine content of foods and diet, the absorption, transport, storage, and excretion of carnitine in humans. The metabolic functions and biosynthesis of carnitine are also reviewed.
Language of Publication
English
Unique Identifier
78100453

Return To Top


MeSH Heading (Major)
Carnitine|*/AN/ME; Food Analysis|*
MeSH Heading
Absorption; Adult; Animal; Biological Transport; Carboxy-Lyases|ME; Carnitine O-Acetyltransferase|ME; Carnitine O-Palmitoyltransferase|ME; Child; Diet; Female; Human; Male; Nutritional Requirements

Publication Type
JOURNAL ARTICLE; REVIEW
ISSN
0002-9165
Country of Publication
UNITED STATES

Record 7 from database: MEDLINE
Return To Top

Title
Carnitine metabolism in human subjects. III. Metabolism in disease.
Author
Mitchell ME
Address
 
Source
Am J Clin Nutr, 1978 Apr, 31:4, 645-59
Abstract
Carnitine metabolism is reviewed in lipid storage myopathies, diabetes, vomiting sickness of Jamaica, malnutrition, hyperthyrodism, Duchenne dystrophy, and a few other disease states.
Language of Publication
English
Unique Identifier
78142111

Return To Top


MeSH Heading (Major)
Carnitine|DF/*ME
MeSH Heading
Adolescence; Adult; Animal; Carnitine Acyltransferases|ME; Child; Diabetes Mellitus|PP; Diabetic Ketoacidosis|PP; Female; Gluconeogenesis|DE; Human; Hyperthyroidism|ME; Hypoglycins|PD/PO; Male; Middle Age; Muscular Diseases|ET; Muscular Dystrophy|ME; Plant Poisoning|PP

Publication Type
JOURNAL ARTICLE; REVIEW
ISSN
0002-9165
Country of Publication
UNITED STATES

Record 8 from database: MEDLINE
Return To Top

Title
The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs [see comments]
Author
Brass EP; Hiatt WR
Address
Department of Medicine, Harbor-UCLA Medical Center, UCLA School of Medicine, Torrance 90509, USA.
Source
J Am Coll Nutr, 1998 Jun, 17:3, 207-15
Abstract
Carnitine is critical for normal skeletal muscle bioenergetics. Carnitine has a dual role as it is required for long-chain fatty acid oxidation, and also shuttles accumulated acyl groups out of the mitochondria. Muscle requires optimization of both of these metabolic processes during peak exercise performance. Theoretically, carnitine availability may become limiting for either fatty acid oxidation or the removal of acyl-CoAs during exercise. Despite the theoretical basis for carnitine supplementation in otherwise healthy persons to improve exercise performance, clinical data have not demonstrated consistent benefits of carnitine administration. Additionally, most of the anticipated metabolic effects of carnitine supplementation have not been observed in healthy persons. The failure to demonstrate clinical efficacy of carnitine may reflect the complex pharmacokinetics and pharmacodynamics of carnitine supplementation, the challenges of clinical trial design for performance endpoints, or the adequacy of endogenous carnitine content to meet even extreme metabolic demands in the healthy state. In patients with end stage renal disease there is evidence of impaired cellular metabolism, the accumulation of metabolic intermediates and increased carnitine demands to support acylcarnitine production. Years of nutritional changes and dialysis therapy may also lower skeletal muscle carnitine content in these patients. Preliminary data have demonstrated beneficial effects of carnitine supplementation to improve muscle function and exercise capacity in these patients. Peripheral arterial disease (PAD) is also associated with altered muscle metabolic function and endogenous acylcarnitine accumulation. Therapy with either carnitine or propionylcarnitine has been shown to increase claudication-limited exercise capacity in patients with PAD. Further clinical research is needed to define the optimal use of carnitine and acylcarnitines as therapeutic modalities to improve exercise performance in disease states, and any potential benefit in healthy individuals.
Language of Publication
English
Unique Identifier
98291376

Return To Top


MeSH Heading (Major)
Carnitine|*AD/TU; Dietary Supplements|*; Exercise|*PH
MeSH Heading
Atherosclerosis|DT; Clinical Trials; Energy Metabolism; Human; Kidney Failure, Chronic|DT; Muscle, Skeletal|ME

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0731-5724
Country of Publication
UNITED STATES

Record 9 from database: MEDLINE
Return To Top
Return To Menu Position #10

Title
Carnitine metabolism and human carnitine deficiency.
Author
Tanphaichitr V; Leelahagul P
Address
Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Source
Nutrition, 1993 May, 9:3, 246-54
Abstract
Carnitine in the human body is derived from the intake of preformed dietary carnitine and biosynthesized carnitine, stemming from the metabolism of lysine and methionine. Carnitine is synthesized in liver and kidney, stored in skeletal muscle, and excreted mainly in urine. Carnitine has two main functions, i.e., transporting long-chain fatty acids into the mitochondrial matrix for beta-oxidation to provide cellular energy and modulating the rise in intramitochondrial acyl-CoA/CoA ratio, which relieves the inhibition of many intramitochondrial enzymes involving glucose and amino acid catabolism. Thus, the main consequence of carnitine deficiency is impaired energy metabolism. Human carnitine deficiency can be either hereditary or acquired. Hereditary carnitine deficiency can be grouped into three clinical entities: myopathic carnitine deficiency, systemic carnitine deficiency, and organic acidurias. Acquired carnitine deficiency is due to inadequate intake, increased requirement, and increased loss of carnitine. The definite diagnosis of carnitine deficiency is based on the determination of free- and acylcarnitine levels in serum, urine, and/or tissues. The estimated safe and adequate daily carnitine intake for adults is 150-500 mumol/day whereas pharmacological doses of carnitine are required for the treatment of hereditary carnitine deficiency.
Language of Publication
English
Unique Identifier
93357583

Return To Top
Return To Menu Position #10


MeSH Heading (Major)
Carnitine|*DF/*ME
MeSH Heading
Animal; Deficiency Diseases|PP; Human; Metabolism, Inborn Errors|PP; Nutritional Requirements

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC
ISSN
0899-9007
Country of Publication
UNITED STATES

Record 10 from database: MEDLINE
Return To Top
Return To Menu Position #10

Title
Antioxidants, carnitine, and choline as putative ergogenic aids.
Author
Kanter MM; Williams MH
Address
Gatorade Sports Science Institute, Barrington, IL 60010, USA.
Source
Int J Sport Nutr, 1995 Jun, 5 Suppl:, S120-31
Abstract
Three nutritional products that have very different mechanisms of action are antioxidant vitamins, carnitine, and choline. Antioxidant vitamins do not appear to have a direct effect on physical performance in well-fed people but have been touted for their ability to detoxify potentially damaging free radicals produced during exercise. Carnitine purportedly enhances lipid oxidation, increases VO2max, and decreases plasma lactate accumulation during exercise. However, studies of carnitine do not generally support its use for ergogenic purposes. Choline supplements have been advocated as a means of preventing the decline in acetylcholine production purported to occur during exercise; this decline may reduce the transmission of contraction-generating impulses across the skeletal muscle, an effect that could impair one's ability to perform muscular work. However, there are no definitive studies in humans that justify choline supplementation. Much of the scientific data regarding the aforementioned nutrients are equivocal and contradictory. Their potential efficacy for improving physical performance remains largely theoretical.
Language of Publication
English
Unique Identifier
96018082

Return To Top
Return To Menu Position #10


MeSH Heading (Major)
Antioxidants|AD/*PD; Carnitine|AD/*PD; Choline|AD/*PD; Exertion|*DE/PH
MeSH Heading
Acetylcholine|ME; Food, Fortified; Human; Muscle, Skeletal|PH; Oxygen Consumption|PH

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
1050-1606
Country of Publication
UNITED STATES

Record 11 from database: MEDLINE
Return To Top
Return To Menu Position #10

Title
Carnitine--a known compound, a novel function in neural cells.
Author
Na…ecz KA; Na…ecz MJ
Address
Department of Muscle Biochemistry, Nencki Institute of Experimental Biology, Warsaw, Poland. KNAL@nencki.gov.pl
Source
Acta Neurobiol Exp (Warsz), 1996, 56:2, 597-609
Abstract
Carnitine (4-N-trimethylammonium-3-hydroxybutyric acid) seems to fulfill in the brain a different role than in peripheral tissues. Carnitine is accumulated by neural cells in a sodium-dependent way. The existence of a novel transporter in plasma membrane, specific to compounds with a polar group in the beta-position with respect to carboxyl group, has been postulated. The presence of a carnitine carrier in the inner mitochondrial membrane has been proven and the protein has been purified. It is postulated that its major role in adult brain would be translocation of acetyl moieties from mitochondria into the cytoplasm for acetylcholine synthesis. The latter process is stimulated by carnitine and choline in a synergistic way in cells utilizing glucose as the main energetic substrate. Carnitine metabolism in neural cells leads to accumulation of different acyl derivatives of carnitine. Palmitoylcarnitine can influence directly the activity of protein kinase C. An involvement of carnitine in a decrease of palmitate pool used for palmitoylation of regulatory proteins has been postulated.
Language of Publication
English
Unique Identifier
96333875

Return To Top
Return To Menu Position #10


MeSH Heading (Major)
Brain|*PH; Carnitine|ME/*PH; Neurons|*PH
MeSH Heading
Acetylcholine|ME; Adult; Animal; Biological Transport; Choline|PH; Human; Intracellular Membranes|ME; Mitochondria|ME

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0065-1400
Country of Publication
POLAND

Record 12 from database: MEDLINE
Return To Top
Return To Menu Position #10

Title
Carnitine palmitoyltransferase deficiency in a college athlete: a case report and literature review.
Author
Faigel HC
Address
University Health Services, Brandeis University, USA.
Source
J Am Coll Health, 1995 Sep, 44:2, 51-4
Abstract
Type II carnitine palmitoyltransferase deficiency is the most common cause of exercise-induced rhabdomyolysis, myoglobinuria, and proximal muscle weakness and pain in young adults. A lack of this enzyme impairs mitochondrial oxidation of long-chain fatty acids and can lead to rhabdomyolysis, myoglobinuria, and renal failure. Carnitine palmitoyltransferase deficiency, unusual but not rare, is often detected by finding elevated creatine phosphokinase level in a routine blood chemistry panel. A case of carnitine palmitoyltransferase deficiency in a college athlete is presented, and the disorder is compared with defective myophosphorylation in McArdle's disease, the next most frequent cause of similar symptoms.
Language of Publication
English
Unique Identifier
96019565

Return To Top
Return To Menu Position #10


MeSH Heading (Major)
Carnitine O-Palmitoyltransferase|*DF; Kidney Failure, Acute|*CO; Myoglobinuria|*CO; Rhabdomyolysis|*CO
MeSH Heading
Adolescence; Case Report; Diagnosis, Differential; Exercise; Female; Glycogen Storage Disease Type V|CO/EN/GE; Human; Mitochondrial Myopathies|CO/EN/GE; Phosphorylation

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW LITERATURE
ISSN
0744-8481
Country of Publication
UNITED STATES

Record 13 from database: MEDLINE
Return To Top
Return To Menu Position #10

Title
New insights into the mitochondrial carnitine palmitoyltransferase enzyme system.
Author
McGarry JD; Sen A; Esser V; Woeltje KF; Weis B; Foster DW
Address
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75235.
Source
Biochimie, 1991 Jan, 73:1, 77-84
Abstract
Dissection of the mitochondrial carnitine palmitoyltransferase (CPT) enzyme system in terms of its structure/function relationships has proved to be a formidable task. Although no one formulation has gained universal agreement we believe that the weight of evidence supports a model with the following features: a) in any given tissue CPT I and CPT II are distinct proteins; b) CPT I, unlike CPT II, is detergent labile; c) within a species CPT II is expressed body wide, whereas CPT I exists as tissue specific isoforms; d) malonyl-CoA and other CPT I inhibitors probably interact at the catalytic center of the enzyme, not with a regulatory subunit. The amino acid sequences of rat and human CPT II (deduced from cDNA clones) show them to be similar proteins (greater than 80% identity) but encoded by mRNAs of significantly different sizes. Efforts to clone and sequence the cDNA for rat liver CPT I are presently underway.
Language of Publication
English
Unique Identifier
91234776

Return To Top
Return To Menu Position #10


MeSH Heading (Major)
Carnitine O-Palmitoyltransferase|CH/*ME; Mitochondria|*EN
MeSH Heading
Amino Acid Sequence; Animal; Human; Isoenzymes|ME; Malonyl Coenzyme A|ME/PD; Mitochondria, Heart|EN; Mitochondria, Liver|EN; Mitochondria, Muscle|EN; Models, Biological; Molecular Sequence Data; Structure-Activity Relationship

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0300-9084
Country of Publication
FRANCE

Record 14 from database: MEDLINE
Return To Top
Return To Menu Position #10

Title
L-carnitine in dialysed patients: the choice of dosage regimen.
Author
Berard E; Iordache A; Barrillon D; Bayle J
Address
Department of Nephrology, University Hospital of Nice, France.
Source
Int J Clin Pharmacol Res, 1995, 15:3, 127-33
Abstract
Although carnitine levels and carnitine therapy have been extensively studied in dialysis patients, the pathophysiology of L-carnitine is poorly understood. The usual therapeutic dose is 20-30 mg/kg, resulting in dramatic increases of circulating levels above the normal values. Guided by studies on its lipidic effect and by our experience of its action on haematocrit, we propose the use of 2-3 mg/kg of L-carnitine in future prospective studies.
Language of Publication
English
Unique Identifier
96274618

Return To Top
Return To Menu Position #10


MeSH Heading (Major)
Carnitine|AD/ME/*TU; Hemodialysis|*AE; Kidney Failure, Chronic|*CO/TH
MeSH Heading
Human

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0251-1649
Country of Publication
SWITZERLAND

Record 15 from database: MEDLINE
Return To Top
Return To Menu Position #10

Title
Pyruvate and hydroxycitrate/carnitine may synergize to promote reverse electron transport in hepatocyte mitochondria, effectively 'uncoupling' the oxidation of fatty acids.
Author
McCarty MF; Gustin JC
Address
NutriGuard Research, Encinitas, CA 92024, USA.
Source
Med Hypotheses, 1999 May, 52:5, 407-16
Abstract
In a recent pilot study, joint administration of pyruvate, hydroxycitrate (HCA), and carnitine to obese subjects was associated with a remarkable rate of body-fat loss and thermogenesis, strongly suggestive of uncoupled fatty-acid oxidation. Hepatocytes possess an uncoupling mechanism--reverse electron transport--that enables fasting ketogenesis to proceed independent of respiratory control. Electrons entering the respiratory chain at the coenzyme Q (CoQ) level via FAD-dependent acyl coA dehydrogenase, can be driven 'up' the chain by the electrochemical proton gradient to reduce NAD+; if these electrons are then shuttled to the cytoplasm, returning to the respiratory chain at the CoQ level, the net result is heat generation at the expense of the proton gradient, enabling the uncoupled flow of electrons to oxygen. Pyruvate's bariatric utility may stem from its ability to catalyze the rapid transport of high-energy electrons from mitochondria to the cytoplasm, thus stimulating electron shuttle mechanisms. By enabling rapid mitochondrial uptake of fatty acids and thus disinhibiting hepatocyte ketogenesis, HCA/carnitine should initiate reverse electron transport: concurrent amplification of electron shuttle mechanisms by pyruvate can be expected to accelerate this reverse electron transport, thereby decreasing the electrochemical proton gradient. As a result, hepatocytes may be able to convert fatty acids to CO2 and heat with little net generation of ATP. These considerations suggest that it may be feasible to render hepatocytes functionally equivalent to activated brown fat, such that stored fat can be selectively oxidized in the absence of caloric restriction. Other measures which enhance the efficiency of hepatocyte electron shuttle mechanisms may increase the efficacy of this strategy.
Language of Publication
English
Unique Identifier
99343391

Return To Top
Return To Menu Position #10


MeSH Heading (Major)
Carnitine|*PD; Citrates|*PD; Electron Transport|*DE; Mitochondria, Liver|DE/*ME; Pyruvates|*PD
MeSH Heading
Animal; Body Temperature Regulation; Drug Synergism; Fatty Acids, Nonesterified|ME; Glucagon|PH; Human; Models, Biological; Pilot Projects; Ubiquinone|ME

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0306-9877
Country of Publication
ENGLAND

Record 16 from database: MEDLINE
Return To Top
Return To Menu Position #10

Title
Carnitine supplementation in soy-based formula-fed infants.
Author
Novak M
Address
Department of Pediatrics, University of Miami School of Medicine, Fla.
Source
Biol Neonate, 1990, 58 Suppl 1:, 89-92
Abstract
Gradual increase of carnitine in plasma, tissues and urine after birth is a normal response of breast-fed infants and those receiving carnitine-containing formulas. Marked reduction of carnitine and acylcarnitines was noted in infants given diets not containing carnitine. These differences prompted the evaluation of the rationale for adding carnitine into soy-based formulas. In healthy term infants the lack of dietary carnitine did not induce deficiency symptoms but reduced the uptake of fatty acids for beta-oxidation. The cumulative effect of various metabolic disorders and carnitine deficient diets may culminate to carnitine deficiency.
Language of Publication
English
Unique Identifier
91091454

Return To Top
Return To Menu Position #10


MeSH Heading (Major)
Carnitine|*AD/BL/DF/UR; Infant Food|*; Infant Nutrition|*; Vegetable Proteins|*
MeSH Heading
Fatty Acids|ME; Human; Infant, Newborn

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0006-3126
Country of Publication
SWITZERLAND

Record 17 from database: MEDLINE
Return To Top
Return To Menu Position #10

Title
Primary and secondary carnitine deficiency syndromes.
Author
Pons R; De Vivo DC
Address
Department of Neurology, Colleen Giblin Laboratories for Pediatric Neurology Research, Columbia-Presbyterian Medical Center, New York, NY, USA.
Source
J Child Neurol, 1995 Nov, 10 Suppl 2:, S8-24
Abstract
The objective of this article is to review primary and secondary causes of carnitine deficiency, emphasizing recent advances in our knowledge of fatty acid oxidation. It is now understood that the cellular metabolism of fatty acids requires the cytosolic carnitine cycle and the mitochondrial beta-oxidation cycle. Carnitine is central to the translocation of the long chain acyl-CoAs across the inner mitochondrial membrane. The mitochondrial beta-oxidation cycle is composed of a newly described membrane-bound system and the classic matrix compartment system. Very long chain acyl-CoA dehydrogenase and the trifunctional enzyme complex are embedded in the inner mitochondrial membrane, and metabolize the long chain acyl-CoAs. The chain shortened acyl-CoAs are further degraded by the well-known system in the mitochondrial matrix. Numerous metabolic errors have been described in the two cycles of fatty acid oxidation; all are transmitted as autosomal recessive traits. Primary or secondary carnitine deficiency is present in all these clinical conditions except carnitine palmitoyltransferase type I and the classic adult form of carnitine palmitoyltransferase type II deficiency. The sole example of primary carnitine deficiency is the genetic defect involving the active transport across the plasmalemmal membrane. This condition responds dramatically to oral carnitine therapy. The secondary carnitine deficiencies respond less obviously to carnitine replacement. These conditions are managed by high carbohydrate, low fat frequent feedings, and vitamin/cofactor supplementation (eg, carnitine, glycine, and riboflavin). Medium chain triglycerides may be useful in the dietary management of patients with inborn errors of the cytosolic carnitine cycle or the mitochondrial membrane-bound long chain specific beta-oxidation system.
Language of Publication
English
Unique Identifier
96155687

Return To Top
Return To Menu Position #10


MeSH Heading (Major)
Carnitine|*ME; Vitamin B Deficiency|*ME
MeSH Heading
Animal; Enzyme Activation; Fatty Acids|ME; Human; Mitochondria|ME; Risk Factors; Support, Non-U.S. Gov't

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC
ISSN
0883-0738
Country of Publication
UNITED STATES

Record 18 from database: MEDLINE
Return To Top
Return To Menu Position #10

Title
Carnitine in human immunodeficiency virus type 1 infection/acquired immune deficiency syndrome.
Author
Mintz M
Address
University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School at Camden 08103, USA.
Source
J Child Neurol, 1995 Nov, 10 Suppl 2:, S40-4
Abstract
There is an increasing body of evidence that subgroups of patients infected with human immunodeficiency virus type 1 possess carnitine deficiency. Secondary carnitine deficiencies in these individuals may result from nutritional deficiencies, gastrointestinal disturbances, renal losses, or shifts in metabolic pathways. However, tissue depletion precipitated by drug toxicities, particularly zidovudine, is a major etiology and concern. Carnitine deficiency may impact on energy and lipid metabolism, causing mitochondrial and immune dysfunction. There are convincing laboratory data showing the in vitro ameliorative effects of L-carnitine supplementation of zidovudine-induced myopathies and lymphocyte function. Studies measuring the impact of L-carnitine supplementation on clinical characteristics are ongoing.
Language of Publication
English
Unique Identifier
96155690

Return To Top
Return To Menu Position #10


MeSH Heading (Major)
Carnitine|*ME; HIV Infections|*ME; HIV-1|*; Vitamin B Deficiency|*ME
MeSH Heading
Human

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0883-0738
Country of Publication
UNITED STATES

Record 19 from database: MEDLINE
Return To Top
Return To Menu Position #10
Return To Menu Position #20

Title
Carnitine deficiency in epilepsy: Risk factors and treatment.
Author
Coulter DL
Address
Department of Pediatrics, Boston University School of Medicine, MA, USA.
Source
J Child Neurol, 1995 Nov, 10 Suppl 2:, S32-9
Abstract
Numerous studies have shown that plasma carnitine levels are significantly lower in patients taking valproate than in controls. Free carnitine deficiency is not uncommon in these patients and also occurs in newborns with seizures and in patients taking other anticonvulsant drugs. Carnitine deficiency in epilepsy results from a variety of etiologic factors including underlying metabolic diseases, nutritional inadequacy, and specific drug effects. The relationship between carnitine deficiency and valproate-induced hepatotoxicity is unclear. Carnitine treatment does not always prevent the emergence of serious hepatotoxicity, but it does alleviate valproate-induced hyperammonemia. These studies suggest that specific risk factors for carnitine deficiency can be identified. Preliminary data suggest that carnitine treatment may benefit high-risk, symptomatic patients and those with free carnitine deficiency. Carnitine treatment is not likely to benefit low-risk, asymptomatic patients and those with normal carnitine levels.
Language of Publication
English
Unique Identifier
96155689

Return To Top
Return To Menu Position #10
Return To Menu Position #20


MeSH Heading (Major)
Carnitine|*ME; Epilepsy|DT/*ME; Vitamin B Deficiency|*ME
MeSH Heading
Human; Liver|DE; Risk Factors; Valproic Acid|TU

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0883-0738
Country of Publication
UNITED STATES

Record 20 from database: MEDLINE
Return To Top
Return To Menu Position #10
Return To Menu Position #20

Title
Biosynthesis and metabolism of carnitine.
Author
Carter AL; Abney TO; Lapp DF
Address
Department of Biochemistry, Medical College of Georgia, Augusta 30912-2100, USA.
Source
J Child Neurol, 1995 Nov, 10 Suppl 2:, S3-7
Abstract
This review article presents the biosynthesis, metabolism, sources, levels, and general functions of carnitine. Emphasis is placed on the expression of carnitine deficiency and insufficiency as well as the causes of these conditions. The various functions of carnitine are discussed as they may relate to disease treatment.
Language of Publication
English
Unique Identifier
96155686

Return To Top
Return To Menu Position #10
Return To Menu Position #20


MeSH Heading (Major)
Carnitine|*BI/*ME
MeSH Heading
Animal; Chemistry; Human

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0883-0738
Country of Publication
UNITED STATES

Record 21 from database: MEDLINE
Return To Top
Return To Menu Position #10
Return To Menu Position #20

Title
Carnitine in neonatal nutrition.
Author
Borum PR
Address
Department of Food Science and Human Nutrition, University of Florida, Gainesville 32611-0370, USA.
Source
J Child Neurol, 1995 Nov, 10 Suppl 2:, S25-31
Abstract
Experimental evidence from several investigators suggests that carnitine is a conditionally essential nutrient for neonates. If carnitine is a conditionally essential nutrient for the neonate, most neonates on total parenteral nutrition in the United States are not receiving adequate nutritional support. The metabolic functions of carnitine are varied and important in several aspects of neonatal physiology. All neonates receiving breast milk receive dietary carnitine and most neonates receiving enteral infant formulas receive dietary carnitine at a level similar to that of the breast-fed neonate. However, most neonates on total parenteral nutrition receive no dietary carnitine. Investigators have been testing the working hypothesis that carnitine is a conditionally essential nutrient for the neonate for many years. This review discusses (1) data supporting the hypothesis, (2) reasons why it has not been either proved or disproved by now, and (3) the author's view of a prudent approach to dietary carnitine supplementation of neonates.
Language of Publication
English
Unique Identifier
96155688

Return To Top
Return To Menu Position #10
Return To Menu Position #20


MeSH Heading (Major)
Carnitine|*ME; Vitamin B Deficiency|*ME
MeSH Heading
Age Factors; Animal; Animals, Newborn; Child Nutrition; Human; Infant, Newborn

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0883-0738
Country of Publication
UNITED STATES

Record 22 from database: MEDLINE
Return To Top
Return To Menu Position #20

Title
Expression and regulation of carnitine palmitoyltransferase-Ialpha and -Ibeta genes.
Author
Cook GA; Park EA
Address
Department of Pharmacology, College of Medicine, The University of Tennessee, Memphis 38163, USA. gcook@utmem1.utmem.edu
Source
Am J Med Sci, 1999 Jul, 318:1, 43-8
Abstract
Two genes control expression of mitochondrial carnitine palmitoyltransferase-I (CPT-I), the enzyme that catalyzes the primary rate-controlling step in fatty acid oxidation. Two CPT-I isoforms have been found--a "liver" isoform (CPT-Ialpha) expressed in most tissues, but not in skeletal muscles, and a "muscle" isoform (CPT-Ibeta) expressed in muscles and adipocytes. Liver CPT-Ialpha increases dramatically at birth, but heart CPT-Ialpha is abundant in the fetus and diminishes at birth. Insulin, thyroid hormone, and fatty acids regulate expression of CPT-Ialpha in liver, whereas electrical stimulation increases CPT-Ibeta and decreases CPT-Ialpha in cardiac myocytes. Both genes are TATA-less and contain Sp1 transcription factor binding sites upstream of the start site of transcription. Multiple transcripts of both CPT-Ialpha and CPT-Ibeta exist, some of which may have roles in regulating fatty acid oxidation.
Language of Publication
English
Unique Identifier
99335245

Return To Top
Return To Menu Position #20


MeSH Heading (Major)
Carnitine O-Palmitoyltransferase|*GE; Fatty Acids|*ME; Gene Expression Regulation, Enzymologic|*; Mitochondria|*EN
MeSH Heading
Animal; Human; Isoenzymes|GE; Mitochondria, Heart|EN; Mitochondria, Liver|EN; Oxidation-Reduction

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0002-9629
Country of Publication
UNITED STATES

Record 23 from database: MEDLINE
Return To Top
Return To Menu Position #20

Title
The role of the carnitine system in peroxisomal fatty acid oxidation.
Author
Ramsay RR
Address
School of Biomedical Sciences, University of St. Andrews, Fife, UK. rrr@st-and.ac.uk
Source
Am J Med Sci, 1999 Jul, 318:1, 28-35
Abstract
Peroxisomes are small, subcellular organelles that play a major role in lipid metabolism. Inherited disorders of peroxisomal structure and metabolism can result from defective assembly, missing protein import transporters, or individual enzyme deficiencies. Molecular studies helped by the range of disorders have now elucidated many of the pathways, including the paths of alpha-oxidation for phytanic acid and beta-oxidation for very-long-chain and branched-chain fatty acids and for bile acid synthesis. The mechanism of the transfer of substrates, intermediates, and products across the membrane is poorly understood. The carnitine system, known to transport activated acyl groups between localized coenzyme A pools, is presented. The evidence for the involvement of carnitine in the transfer of activated acyl groups to and from the peroxisomes is reviewed.
Language of Publication
English
Unique Identifier
99335243

Return To Top
Return To Menu Position #20


MeSH Heading (Major)
Carnitine|*ME; Fatty Acids|*ME; Microbodies|*ME
MeSH Heading
Animal; Human; Lipid Peroxidation; Oxidation-Reduction

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0002-9629
Country of Publication
UNITED STATES

Record 24 from database: MEDLINE
Return To Top
Return To Menu Position #20

Title
Carnitine-acylcarnitine translocase deficiency.
Author
Pande SV
Address
Laboratory of Intermediary Metabolism, Clinical Research Institute of Montreal, Quebec, Canada. spande@sprint.ca
Source
Am J Med Sci, 1999 Jul, 318:1, 22-7
Abstract
Carnitine-acylcarnitine translocase deficiency, like other defects of mitochondrial fatty acid oxidation, is an autosomal, recessively inherited disorder. When the deficiency is near total, it is usually fatal, affects life soon after birth, and constitutes one of the causes of skeletal muscle myopathy, cardiac and liver abnormalities, and childhood sudden death. The presenting features have included neonatal distress, convulsions, hypoglycemia, hyperammonemia, hypoketonemia, intermittent dicarboxyluria, hypothermia, apnea, neurological deterioration, and hypocarnitinemia with grossly elevated acylcarnitines. Two cases of partial translocase deficiency (4-6% residual activity) with milder symptoms and without cardiac involvement have also been identified. Evidence so far indicates that the translocase protein is the product of a single gene. In two cases of translocase deficiency, the accompanying mutations have been identified. The benefits of prenatal diagnosis have been provided to the affected families by assays of the translocase and/or fatty acid oxidation in cultured amniotic/villous cells. In one such case genetic counseling was made possible even when the only specimen available from a deceased sibling was the Guthrie card.
Language of Publication
English
Unique Identifier
99335242

Return To Top
Return To Menu Position #20


MeSH Heading (Major)
Carnitine Acyltransferases|*DF; Metabolism, Inborn Errors|CO/*DI/*EN
MeSH Heading
Diagnosis, Differential; Fatty Acids|ME; Human; Infant, Newborn; Prenatal Diagnosis; Support, Non-U.S. Gov't

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0002-9629
Country of Publication
UNITED STATES

Record 25 from database: MEDLINE
Return To Top
Return To Menu Position #20

Title
Primary and secondary alterations of neonatal carnitine metabolism.
Author
Scaglia F; Longo N
Address
Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Source
Semin Perinatol, 1999 Apr, 23:2, 152-61
Abstract
Carnitine plays an essential role in the transfer of long-chain fatty acids across the inner mitochondrial membrane, in the detoxification of acyl moieties, and in maintaining normal levels of free coenzyme A. Although carnitine can be synthesized in liver and kidney, normal adults obtain the majority of carnitine from the diet. Preterm newborns have a reduced capacity to synthesize carnitine. Total parenteral nutrition lacks carnitine and exposes very low birth weight infants to carnitine deficiency, with decreased production of ketones from long-chain fatty acids. Supplementation with low doses of carnitine improves nitrogen balance and growth in these infants. Carnitine deficiency can be part of a number of inherited and acquired diseases. Primary carnitine deficiency is an autosomal recessive disorder characterized by increased losses of carnitine in the urine and decreased accumulation in the heart and skeletal muscle caused by defective carnitine transport. This condition is corrected by high-dose carnitine supplementation. Secondary carnitine deficiency can be caused by increased losses, pharmacological therapy, or a number of inherited metabolic disorders that must be correctly diagnosed before initiating carnitine supplementation.
Language of Publication
English
Unique Identifier
99260309

Return To Top
Return To Menu Position #20


MeSH Heading (Major)
Carnitine|AD/*DF/*ME
MeSH Heading
Diet; Fatty Acids|ME; Human; Infant, Newborn; Metabolism, Inborn Errors|DI/TH; Oxidation-Reduction

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0146-0005
Country of Publication
UNITED STATES

Record 26 from database: MEDLINE
Return To Top
Return To Menu Position #20

Title
The roles of glucose-induced metabolic hypoxia and imbalances in carnitine metabolism in mediating diabetes-induced vascular dysfunction.
Author
Williamson JR; Arrigoni Martelli E
Address
Department of Pathology, Washington University School of Medicine, St. Louis.
Source
Int J Clin Pharmacol Res, 1992, 12:5-6, 247-52
Abstract
Investigations were initiated to examine the rate of imbalances in carnitine metabolism in the pathogenesis of diabetic vascular changes in the retina, peripheral nerves, aorta and kidney. It appears that glucose/diabetes-induced vascular dysfunction and early vascular structural changes are mediated by hyperglycaemic hypoxia i.e. glucose-induced metabolic imbalances that cause an increase in the reduced nicotinamide-adenine dinucleotide/nicotinic acid dehydrogenase ratio, and are linked to imbalances in carnitine metabolism.
Language of Publication
English
Unique Identifier
93246324

Return To Top
Return To Menu Position #20


MeSH Heading (Major)
Blood Glucose|*ME; Carnitine|*ME; Cell Hypoxia|*; Diabetic Angiopathies|*ET/ME
MeSH Heading
Animal; Human; NAD|ME; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0251-1649
Country of Publication
SWITZERLAND

Record 27 from database: MEDLINE
Return To Top
Return To Menu Position #20

Title
Clinical and biochemical aspects of carnitine deficiency and insufficiency: transport defects and inborn errors of beta-oxidation.
Author
Angelini C; Vergani L; Martinuzzi A
Address
Regional Neuromuscular Center, University of Padova, Italy.
Source
Crit Rev Clin Lab Sci, 1992, 29:3-4, 217-42
Abstract
Carnitine is required for entry of long chain fatty acids into mitochondria where beta-oxidation occurs. Primary carnitine deficiency, due to a generic defect in cellular carnitine transport, exists in myopathic and systemic forms. Secondary carnitine deficiency may be due to multiplicity of inherited abnormalities, including deficiencies in carnitine palmitoyl-transferase acyl-CoA dehydrogenases, electron transfer flavoprotein, and 3-ketoacyl-CoA-thiolase. The clinical features, diagnosis, and treatment of these conditions are described.
Language of Publication
English
Unique Identifier
93143862

Return To Top
Return To Menu Position #20


MeSH Heading (Major)
Carnitine|*DF/ME; Vitamin B Deficiency|*ME
MeSH Heading
Biological Transport, Active; Fatty Acids|ME; Human; Metabolism, Inborn Errors|ME; Mitochondria|ME; Oxidation-Reduction; Support, Non-U.S. Gov't

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
1040-8363
Country of Publication
UNITED STATES

Record 28 from database: MEDLINE
Return To Top
Return To Menu Position #20
Return To Menu Position #30

Title
Biological roles of L-carnitine in perinatal metabolism.
Author
Arenas J; Rubio JC; Martín MA; Campos Y
Address
Centro de InvestigaciÆon Hospital Universitario 12 de Octubre, Madrid, Spain. jarenas@h12o.es
Source
Early Hum Dev, 1998 Dec, 53 Suppl:, S43-50
Abstract
Carnitine performs a crucial role in the energy supply of tissues during fetal life and in the neonatal period by controlling the influx of fatty acids into mitochondria. Carnitine also facilitates the oxidation of pyruvate and branched chain amino acids, and contributes to the protection of cells from the deleterious actions of acyl CoAs. Carnitine further acts as a secondary antioxidant, favouring fatty acid replacement within previously oxidatively damaged membrane phospholipids. Availability of L-carnitine is essential in the developing fetus for processes underlying fetal maturation. L-carnitine is also essential for development of hepatic ketone synthesis, a central pathway for neonatal energy metabolism. Ketone bodies inhibit the oxidation of both glucose and lactate, sparing these metabolic substrates for biosynthetic functions.
Language of Publication
English
Unique Identifier
99200799

Return To Top
Return To Menu Position #20
Return To Menu Position #30


MeSH Heading (Major)
Carnitine|*PH; Fetus|*ME
MeSH Heading
Energy Metabolism; Fatty Acids, Nonesterified|ME; Human; Infant, Newborn; Ketone Bodies|ME; Liver|ME; Mitochondria|ME; Oxidation-Reduction; Support, Non-U.S. Gov't

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0378-3782
Country of Publication
IRELAND

Record 29 from database: MEDLINE
Return To Top
Return To Menu Position #20
Return To Menu Position #30

Title
Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients.
Author
Brass EP
Address
Department of Medicine, Harbor-UCLA Medical Center, Torrance, USA.
Source
Clin Ther, 1995 Mar, 17:2, 176-85; discussion 175
Abstract
Clinical observations have suggested that carnitine supplementation may be beneficial to a subset of patients receiving chronic hemodialysis. In the absence of definitive clinical trials, the clinician must decide for an individual patient whether a trial of carnitine therapy is justified. The institution of carnitine therapy is further complicated by the availability of oral and intravenous dosing forms and by the compound's complex pharmacokinetics. The oral systemic bioavailability of carnitine in normal subjects is 5% to 16%, with peak plasma carnitine concentrations reached 2 to 6 hours after dosing. Carnitine is initially distributed into extracellular water and then more slowly enters tissue compartments with complex kinetics. Elimination of carnitine is through the urine or dialysate. Intravenous carnitine administration results in large peak plasma concentrations and assures systemic bioavailability. Orally administered carnitine has been reported to have clinical efficacy in hemodialysis patients in doses of 2 to 4 g per day in divided doses. Intravenous carnitine has also been widely used in clinical trials in attempts to demonstrate efficacy in the hemodialysis population; however, the available data do not establish the superiority of the intravenous formulation over the oral form. Intravenous carnitine may have theoretical advantages in initiating treatment when high peak concentrations are required to facilitate carnitine reaching nonhepatic tissue sites or when oral carnitine therapy is not feasible due to poor tolerance or compliance. Although comparative trials are lacking, it is probable that oral therapy can be used for long-term maintenance, regardless of which formulation was used to initiate therapy. The decision to use carnitine therapy, as well as the dose and route of administration, requires individualization based on the clinical status of the patient and the goals of therapy.
Language of Publication
English
Unique Identifier
95339370

Return To Top
Return To Menu Position #20
Return To Menu Position #30


MeSH Heading (Major)
Carnitine|*AD/*PK; Hemodialysis|*; Kidney Failure, Chronic|*ME
MeSH Heading
Biological Availability; Human; Muscles|ME; Tissue Distribution

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0149-2918
Country of Publication
UNITED STATES

Record 30 from database: MEDLINE
Return To Top
Return To Menu Position #20
Return To Menu Position #30

Title
Carnitine function and requirements during the life cycle.
Author
Rebouche CJ
Address
Department of Pediatrics, University of Iowa, Iowa City 52242.
Source
FASEB J, 1992 Dec, 6:15, 3379-86
Abstract
L-Carnitine has been described as a "conditionally essential" nutrient for humans. Segments of the human population suggested as having a requirement for carnitine include infants (premature and full-term), patients on long-term parenteral nutrition, and perhaps children. The evidence to support these claims includes 1) low circulating carnitine concentrations; 2) abnormal (or at least different) circulating metabolite concentrations (free fatty acids, triglycerides, ketone bodies), and 3) very limited and inconsistent growth data. A number of subjective observations and anecdotal case reports have been offered in support of a requirement for carnitine. Exogenous carnitine is required to maintain "normal" (in the epidemiologic sense) plasma or serum carnitine concentrations in humans of all ages. But "functional carnitine deficiency," defined by abnormal clinical presentation correctable by carnitine administration, has not been demonstrated in an otherwise normal (nonpathologic) population. On the other hand, nutritional or pharmacological intervention with carnitine or its esters may be beneficial for very premature infants, infants and children with various clinical conditions associated with low circulating carnitine concentrations, and in some chronic diseases associated with the aging process.
Language of Publication
English
Unique Identifier
93099945

Return To Top
Return To Menu Position #20
Return To Menu Position #30


MeSH Heading (Major)
Aging|*PH; Carnitine|*PH; Nutrition|*
MeSH Heading
Adolescence; Adult; Aged; Animal; Child; Child, Preschool; Female; Human; Infant; Infant, Newborn; Male; Middle Age

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0892-6638
Country of Publication
UNITED STATES

Record 31 from database: MEDLINE
Return To Top
Return To Menu Position #20
Return To Menu Position #30

Title
Carnitine palmitoyltransferase: a viable target for the treatment of NIDDM?
Author
Anderson RC
Address
Novartis Pharmaceuticals Corporation, Department of Metabolic and Cardiovascular Diseases, Summit, NJ 07901, USA.
Source
Curr Pharm Des, 1998 Feb, 4:1, 1-16
Abstract
Inhibition of fatty acid oxidation is well recognized as a potentially effective mechanism for controlling glycemia in non-insulin-dependent diabetes mellitus (NIDDM). However, a direct targeting of inhibition of the intramitochondrial beta-oxidation pathway or an indirect modulation of fatty acid oxidation by inhibition of substrate release from adipose stores has been fraught with lack of efficacy, unacceptable side-effects or both. Focus has therefore recently been directed towards the carnitine palmitoyltransferase (CPT) system, a three-component system necessary for the transfer of long-chain fatty acids into the intramitochondrial matrix. This article will briefly review the background for fatty acid oxidation inhibition in NIDDM and then focus on the progress in the biological understanding and drug discovery targeting of the CPT system for the treatment of NIDDM. Based upon the review, it is concluded that mechanism-based hepatic and myocardial toxicities in normal animals and a potential for a lack of human efficacy may pose insurmountable hurdles for the development of CPT inhibitors for the treatment of NIDDM.
Language of Publication
English
Unique Identifier
99212779

Return To Top
Return To Menu Position #20
Return To Menu Position #30


MeSH Heading (Major)
Carnitine O-Palmitoyltransferase|*AI; Diabetes Mellitus, Non-Insulin-Dependent|*DT; Enzyme Inhibitors|*PD/TU; Fatty Acids|*ME; Mitochondria|*ME
MeSH Heading
Animal; Carnitine Acyltransferases|AI; Human; Malonyl Coenzyme A|AI; Oxidation-Reduction

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC
ISSN
1381-6128
Country of Publication
NETHERLANDS

Record 32 from database: MEDLINE
Return To Top
Return To Menu Position #30

Title
Protection of the brain by carnitine.
Author
Igisu H; Matsuoka M; Iryo Y
Address
Department of Environmental Toxicology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Source
Sangyo Eiseigaku Zasshi, 1995 Mar, 37:2, 75-82
Abstract
Carnitine (beta-hydroxy-gamma-trimethylammonium butyrate) is widely distributed in the body including the nervous system. Its physiological function, viz. a carrier of long-chain fatty acids through the inner mitochondrial membrane, has been well established. In this review, mainly based on our experiments, we discuss the possibility that carnitine may have effects other than the "physiological" function and that it may be a potent protector of the brain. When mice were exposed to ammonia (intraperitoneal injection of ammonium acetate), they developed seizures and concentrations of brain energy metabolites were altered; ATP and phosphocreatine decreased while ADP, AMP, pyruvate and lactate increased. The seizures and changes in brain energy metabolites were clearly suppressed when the mice were pre-treated with carnitine. Furthermore, changes in energy metabolites in the brain caused by severe ischemia (decapitation) were also suppressed by carnitine. Since D-carnitine showed similar effects as those of L-carnitine, the effects seem due to function(s) of carnitine yet to be defined. Intrinsic substances including carnitine appear to deserve further studies for possible use in protecting the brain.
Language of Publication
English
Unique Identifier
95269148

Return To Top
Return To Menu Position #30


MeSH Heading (Major)
Brain|DE/*ME; Carnitine|*PH
MeSH Heading
Ammonia|TO; Animal; Cerebral Ischemia|PC; Energy Metabolism; Human; Mice; Seizures|CI/PC; Taurine|PH

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
1341-0725
Country of Publication
JAPAN

Record 33 from database: MEDLINE
Return To Top
Return To Menu Position #30

Title
Fatal carnitine palmitoyltransferase II deficiency in a newborn: new phenotypic features.
Author
Pierce MR; Pridjian G; Morrison S; Pickoff AS
Address
Department of Pediatrics, Hayward Genetics Center, USA.
Source
Clin Pediatr (Phila), 1999 Jan, 38:1, 13-20
Abstract
We describe the term male infant of asymptomatic, healthy nonconsanguineous parents presenting on the first day of life with nonketotic hypoglycemia, seizures, hepatomegaly, cardiomegaly with biventricular hypertrophy, and ventricular arrhythmias. Cranial ultrasound revealed cystic dysplasia with several foci of hyperechogenicity within the right basal ganglia. Free carnitine was markedly decreased in the urine and plasma with a pronounced elevation of plasma long-chain acylcarnitines. Fibroblast carnitine palmitoyltransferase II activity was reduced to 26% and 38% in the father and mother, respectively. The infant expired on day 5 of life from malignant ventricular tachy-arrhythmias. Diffuse lipid accumulation was evident at autopsy, including in the liver, heart, kidney, adrenal cortex, skeletal muscle, and lungs. This new case of infantile CPT-II deficiency illustrates the severity of the early onset form of CPT-II deficiency.
Language of Publication
English
Unique Identifier
99123712

Return To Top
Return To Menu Position #30


MeSH Heading (Major)
Carnitine O-Palmitoyltransferase|*DF
MeSH Heading
Abnormalities, Multiple|GE; Case Report; Deficiency Diseases|GE/MO; Fatal Outcome; Human; Infant, Newborn; Male; Phenotype

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW LITERATURE
ISSN
0009-9228
Country of Publication
UNITED STATES

Record 34 from database: MEDLINE
Return To Top
Return To Menu Position #30

Title
Rate-dependent distal renal tubular acidosis and carnitine palmitoyltransferase I deficiency.
Author
Bergman AJ; Donckerwolcke RA; Duran M; Smeitink JA; Mousson B; Vianey Saban C; Poll The BT
Address
Department of Metabolic Diseases, University Children's Hospital, Het Wilhelmina Kinderziekenhuis, Utrecht, The Netherlands.
Source
Pediatr Res, 1994 Nov, 36:5, 582-8
Abstract
An infant girl presented with recurrent episodes of Reye-like syndrome associated with hypoketosis and plasma carnitine levels in the high-normal range. A liver biopsy revealed massive macrovesicular steatosis. Ketogenesis was absent after a long-chain triglyceride loading test; in contrast, the medium-chain triglyceride loading test resulted in a brisk rise in plasma ketone concentration. Carnitine palmitoyltransferase I deficiency was demonstrated in cultured skin fibroblasts. Hypoglycemia was only found once in the neonatal period. Renal carnitine handling was normal except for a higher renal threshold for free carnitine. Mild, persistent metabolic acidosis was a constant feature, even during periods between metabolic decompensation. Evaluation of the renal acidification capacity showed a failure to acidify the urine during spontaneous acidosis but increased acid excretion and a normal decrease of urinary pH after acid loading. Also, a small difference between urine and blood PCO2 was found after bicarbonate administration. This acidification defect can best be explained as an abnormality in distal tubular H+ secretion: a rate-dependent distal tubular acidosis.off is speculated that long-chain acylcarnitines, substances that cannot be formed by carnitine palmitoyltransferase I-deficient patients, play an essential role in renal acid-base homeostasis.
Language of Publication
English
Unique Identifier
95183348

Return To Top
Return To Menu Position #30


MeSH Heading (Major)
Acidosis, Renal Tubular|BL/*EN; Carnitine|*BL; Carnitine O-Palmitoyltransferase|*DF; Reye Syndrome|BL/*EN
MeSH Heading
Biological Transport|PH; Case Report; Comparative Study; Female; Human; Hydrogen-Ion Concentration; Infant, Newborn; Kidney Function Tests; Protons; Secretory Rate|PH; Sodium Bicarbonate|DU/ME

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW OF REPORTED CASES
ISSN
0031-3998
Country of Publication
UNITED STATES

Record 35 from database: MEDLINE
Return To Top
Return To Menu Position #30

Title
Interactive regulation of the pyruvate dehydrogenase complex and the carnitine palmitoyltransferase system.
Author
Sugden MC; Holness MJ
Address
Department of Biochemistry (Basic Medical Sciences), Queen Mary and Westfield College, University of London, U.K.
Source
FASEB J, 1994 Jan, 8:1, 54-61
Abstract
The review examines the mechanisms regulating the activities of the two key enzymes determining rates of glucose and fatty acid oxidation, i.e., the pyruvate dehydrogenase (PDH) complex and the carnitine palmitoyltransferase (CPT) system. The review also evaluates the regulatory importance of gene expression in the control of tissue fuel selection within the context of substrate competition between glucose and fatty acids. It identifies a strong indirect input of nutrient-gene interactions in the control of pyruvate oxidation through the regulated provision of pyruvate as a substrate for PDH and as an inhibitor of PDH kinase. Nutrient-gene interactions are also identified in relation to the regulation of CPT I activity by malonyl-CoA (inhibitor) and by the provision of long-chain acyl-CoA (substrate/activator), the latter via the hydrolysis of plasma or tissue triacylglycerol (by lipoprotein lipase and hormone-sensitive lipase, respectively). We discuss how such regulation is reinforced by long-term modulation of PDH kinase-specific activity and CPT I maximal activity. We also explore the role of mechanisms operating at the levels of the PDH complex and the CPT system that act to promote and accelerate a switch in fuel utilization once a committed change in nutrient supply has been established. In particular, we discuss the regulatory influences exerted by altered sensitivities of PDH kinase to inhibition by pyruvate and CPT I to inhibition by malonyl-CoA, respectively.
Language of Publication
English
Unique Identifier
94131216

Return To Top
Return To Menu Position #30


MeSH Heading (Major)
Carnitine O-Palmitoyltransferase|GE/*ME; Nutrition|*PH; Pyruvate Dehydrogenase Complex|GE/*ME
MeSH Heading
Animal; Gene Expression Regulation; Human; Support, Non-U.S. Gov't

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0892-6638
Country of Publication
UNITED STATES

Record 36 from database: MEDLINE
Return To Top
Return To Menu Position #30

Title
Molecular mechanism of acute ammonia toxicity and of its prevention by L-carnitine.
Author
Felipo V; Kosenko E; Miñana MD; Marcaida G; Grisolía S
Address
Instituto de Investigaciones CitolÆogicas, FundaciÆon Valenciana de Investigaciones BiomÆedicas, Valencia, Spain.
Source
Adv Exp Med Biol, 1994, 368:, 65-77
Abstract
In summary, we propose that acute ammonia intoxication leads to increased extracellular concentration of glutamate in brain and results in activation of the NMDA receptor. Activation of this receptor mediates ATP depletion and ammonia toxicity since blocking the NMDA receptor with MK-801 prevents both phenomena. Ammonia-induced metabolic alterations (in glycogen, glucose, pyruvate, lactate, glutamine, glutamate, etc) are not prevented by MK-801 and, therefore, it seems that they do not play a direct role in ammonia-induced ATP depletion nor in the molecular mechanism of acute ammonia toxicity. The above results suggest that ammonia-induced ATP depletion is due to activation of Na+/K(+)-ATPase, which, in turn, is a consequence of decreased phosphorylation by protein kinase C. This can be due to decreased activity of PKC or to increased activity of a protein phosphatase. We also show that L-carnitine prevents glutamate toxicity in primary neuronal cultures. The results shown indicate that carnitine increases the affinity of glutamate for the quisqualate type (including metabotropic) of glutamate receptors. Also, blocking the metabotropic receptor with AP-3 prevents the protective effect of L-carnitine, indicating that activation of this receptor mediates the protective effect of carnitine. We suggest that the protective effect of carnitine against acute ammonia toxicity in animals is due to the protection against glutamate neurotoxicity according to the above mechanisms.
Language of Publication
English
Unique Identifier
95259576

Return To Top
Return To Menu Position #30


MeSH Heading (Major)
Ammonia|AI/*TO; Carnitine|*PD
MeSH Heading
Animal; Brain Chemistry|DE/PH; Human; Support, Non-U.S. Gov't

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0065-2598
Country of Publication
UNITED STATES

Record 37 from database: MEDLINE
Return To Top
Return To Menu Position #30

Title
L-Carnitine: therapeutic applications of a conditionally-essential amino acid.
Author
Kelly GS
Address
 
Source
Altern Med Rev, 1998 Oct, 3:5, 345-60
Abstract
A trimethylated amino acid roughly similar in structure to choline, carnitine is a cofactor required for transformation of free long-chain fatty acids into acylcarnitines, and for their subsequent transport into the mitochondrial matrix, where they undergo beta-oxidation for cellular energy production. Mitochondrial fatty acid oxidation is the primary fuel source in heart and skeletal muscle, pointing to the relative importance of this nutrient for proper function in these tissues. Although L-carnitine deficiency is an infrequent problem in a healthy, well-nourished population consuming adequate protein, many individuals within the population appear to be somewhere along a continuum, characterized by mild deficiency at one extreme, and tissue pathology at the other. Conditions which seem to benefit from exogenous supplementation of L-carnitine include anorexia, chronic fatigue, coronary vascular disease, diphtheria, hypoglycemia, male infertility, muscular myopathies, and Rett syndrome. In addition, preterm infants, dialysis patients, and HIV+ individuals seem to be prone to a deficiency of L-carnitine, and benefit from supplementation. Although available data on L-carnitine as an ergogenic aid is not compelling, under some experimental conditions pretreatment has favored aerobic processes and resulted in improved endurance performance.
Language of Publication
English
Unique Identifier
99021822

Return To Top
Return To Menu Position #30


MeSH Heading (Major)
Carnitine|DF/PK/*TU
MeSH Heading
Child; Drug Interactions; Female; Human; Male; Pregnancy

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
1089-5159
Country of Publication
UNITED STATES

Record 38 from database: MEDLINE
Return To Top
Return To Menu Position #30

Title
Carnitine metabolism and its regulation in microorganisms and mammals.
Author
Rebouche CJ; Seim H
Address
Department of Pediatrics, University of Iowa College of Medicine, Iowa City 52242, USA. charles-rebouche@uiowa.edu
Source
Annu Rev Nutr, 1998, 18:, 39-61
Abstract
In procaryotes, L-carnitine may be used as both a carbon and nitrogen source for aerobic growth, or the carbon chain may be used selectively following cleavage trimethylamine. Under anaerobic conditions and in the absence of preferred substrates, some bacteria use carnitine, via crotonobetaine, as an electron acceptor. Formation of trimethylamine and lambda-butyrobetaine (from reduction of crotonobetaine) from L-carnitine by enteric bacteria has been demonstrated in rats and humans. Carnitine is not degraded by enzymes of eukaryotic origin. In higher organisms, carnitine has specific functions in intermediary metabolism. Concentrations of carnitine and its esters in cells of eukaryotes are rigorously maintained to provide optimal function. Carnitine homeostasis in mammals is preserved by a modest rate of endogenous synthesis, absorption from dietary sources, efficient reabsorption, and mechanisms present in most tissues that establish and maintain substantial concentration gradients between intracellular and extracellular carnitine pools.
Language of Publication
English
Unique Identifier
98371491

Return To Top
Return To Menu Position #30


MeSH Heading (Major)
Bacteria|*ME; Carnitine|AD/CH/*ME/PH
MeSH Heading
Animal; Diet; Homeostasis; Human; Kidney|ME

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC
ISSN
0199-9885
Country of Publication
UNITED STATES

Record 39 from database: MEDLINE
Return To Top
Return To Menu Position #30
Return To Menu Position #40

Title
Genetic disorders of carnitine metabolism and their nutritional management.
Author
Kerner J; Hoppel C
Address
Department of Veteran Affairs Medical Center, Department of Nutrition, Cleveland, USA.
Source
Annu Rev Nutr, 1998, 18:, 179-206
Abstract
Carnitine functions as a substrate for a family of enzymes, carnitine acyltransferases, involved in acyl-coenzyme A metabolism and as a carrier for long-chain fatty acids into mitochondria. Carnitine biosynthesis and/or dietary carnitine fulfill the body's requirement for carnitine. To date, a genetic disorder of carnitine biosynthesis has not been described. A genetic defect in the high-affinity plasma membrane carnitine-carrier(in) leads to renal carnitine wasting and primary carnitine deficiency. Myopathic carnitine deficiency could be due to an increase in efflux moderated by the carnitine-carrier(out). Defects in the carnitine transport system for fatty acids in mitochondria have been described and are being examined at the molecular and pathophysiological levels. the nutritional management of these disorders includes a high-carbohydrate, low-fat diet and avoidance of those events that promote fatty acid oxidation, such as fasting, prolonged exercise, and cold. Large-dose carnitine treatment is effective in systemic carnitine deficiency.
Language of Publication
English
Unique Identifier
98371496

Return To Top
Return To Menu Position #30
Return To Menu Position #40


MeSH Heading (Major)
Carnitine|*DF/*ME; Metabolism, Inborn Errors|*DH; Nutrition|*
MeSH Heading
Animal; Diet, Fat-Restricted; Dietary Carbohydrates|AD; Fatty Acids|ME; Human; Mitochondria|ME; Oxidation-Reduction; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC
ISSN
0199-9885
Country of Publication
UNITED STATES

Record 40 from database: MEDLINE
Return To Top
Return To Menu Position #30
Return To Menu Position #40

Title
Carnitine and cardiac interstitium.
Author
Hülsmann WC; Peschechera A; Arrigoni Martelli E
Address
Thoraxcenter, Erasmus University, Rotterdam, The Netherlands.
Source
Cardioscience, 1994 Jun, 5:2, 67-72
Abstract
An important part of (acyl)carnitine may be stored in interstitial spaces and the external surface of adjacent cells. A high concentration of carnitine in the direct vicinity of cells may enhance the synthesis and export of long-chain acylcarnitine. Long-chain acylcoenzyme A, from which long-chain acyl carnitine is formed, cannot penetrate intact cell membranes. During hypoperfusion or ischemia, when long-chain acylcoenzyme A accumulates due to hampered fatty acid oxidation, there is an increased formation of long-chain acyl carnitine which diffuses into the interstitium and adjacent vascular endothelial cells. Due to its lipophilic nature and net positive charge (limitation of carboxyl-group dissociation in ischemic acidosis), long-chain acyl carnitine may decrease the affinity of Ca2+ to the cell surface and prevent Ca2+ overload of cells. The advantage of carnitine over many other cationic amphiphiles in the protection of areas of ischemia is that long-chain acyl carnitine is formed and stored only in ischemic areas.
Language of Publication
English
Unique Identifier
95002604

Return To Top
Return To Menu Position #30
Return To Menu Position #40


MeSH Heading (Major)
Carnitine|BI/*ME; Myocardial Ischemia|*PP; Myocardium|CY/*ME
MeSH Heading
Animal; Calcium Channels|ME; Heart|PH; Human; Oxygen|ME; Rats

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
1015-5007
Country of Publication
ITALY

Record 41 from database: MEDLINE
Return To Top
Return To Menu Position #30
Return To Menu Position #40

Title
Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake.
Author
Stanley CA; DeLeeuw S; Coates PM; Vianey Liaud C; Divry P; Bonnefont JP; Saudubray JM; Haymond M; Trefz FK; Breningstall GN; et al
Address
Division of Endocrinology/Diabetes, Children's Hospital of Philadelphia, PA 19104.
Source
Ann Neurol, 1991 Nov, 30:5, 709-16
Abstract
A defect in intracellular uptake of carnitine has been identified in patients with severe carnitine deficiency. To define the clinical manifestations of this disorder, the presenting features of 15 affected infants and children were examined. Progressive cardiomyopathy, with or without chronic muscle weakness, was the most common presentation (median age of onset, 3 years). Other patients presented with episodes of fasting hypoglycemia during the first 2 years of life before cardiomyopathy had become apparent. A defect in carnitine uptake was demonstrable in fibroblasts and leukocytes from patients. The defect also appears to be expressed in muscle and kidney. Concentrations of plasma carnitine and rates of carnitine uptake in parents were intermediate between affected patients and normal control subjects, consistent with recessive inheritance. Early recognition and treatment with high doses of oral carnitine may be life-saving in this disorder of fatty acid oxidation.
Language of Publication
English
Unique Identifier
92109441

Return To Top
Return To Menu Position #30
Return To Menu Position #40


MeSH Heading (Major)
Carnitine|*PK/TU; Coma|DT/GE/*ME; Lipid Metabolism, Inborn Errors|DT/GE/*ME; Myocardial Diseases|DT/GE/*ME
MeSH Heading
Biological Transport; Case Report; Cells, Cultured; Child; Child, Preschool; Fatty Acids|ME; Female; Fibroblasts|ME; Genes, Recessive; Human; Hypoglycemia|GE/ME; Kidney|ME; Leukocytes|ME; Male; Mitochondria|ME; Muscles|ME; Oxidation-Reduction; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW OF REPORTED CASES
ISSN
0364-5134
Country of Publication
UNITED STATES

Record 42 from database: MEDLINE
Return To Top
Return To Menu Position #30
Return To Menu Position #40

Title
Ascorbic acid and carnitine biosynthesis.
Author
Rebouche CJ
Address
Department of Pediatrics, University of Iowa College of Medicine, Iowa City 52242.
Source
Am J Clin Nutr, 1991 Dec, 54:6 Suppl, 1147S-1152S
Abstract
It has been suggested that early features of scurvy (fatigue and weakness) may be attributed to carnitine deficiency. Ascorbate is a cofactor for two alpha-ketoglutarate-requiring dioxygenase reactions (epsilon-N-trimethyllysine hydroxylase and gamma-butyrobetaine hydroxylase) in the pathway of carnitine biosynthesis. Carnitine concentrations are variably low in some tissues of scorbutic guinea pigs. Ascorbic acid deficiency in guinea pigs resulted in decreased activity of hepatic gamma-butyrobetaine hydroxylase and renal but not hepatic epsilon-N-trimethyllsine hydroxylase when exogenous substrates were provided. It remains unclear whether vitamin C deficiency has a significant impact on the overall rate of carnitine synthesis from endogenous substrates. Nevertheless, results of studies of enzyme preparations and perfused liver in vitro and of scorbutic guinea pigs in vivo provide compelling evidence for participation of ascorbic acid in carnitine biosynthesis.
Language of Publication
English
Unique Identifier
92074394

Return To Top
Return To Menu Position #30
Return To Menu Position #40


MeSH Heading (Major)
Ascorbic Acid|*PD; Carnitine|*BI/BL
MeSH Heading
Animal; Ascorbic Acid Deficiency|BL; Human; Hydroxylases|ME; Hydroxylation

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0002-9165
Country of Publication
UNITED STATES

Record 43 from database: MEDLINE
Return To Top
Return To Menu Position #40

Title
A role for carnitine in medium-chain fatty acid metabolism?
Address
 
Source
Nutr Rev, 1991 Aug, 49:8, 243-5
Abstract
Medium-chain triglycerides do not require carnitine for mitochondrial transport. However, new data suggest that carnitine may play a role in their utilization.
Language of Publication
English
Unique Identifier
92066247

Return To Top
Return To Menu Position #40


MeSH Heading (Major)
Carnitine|*PH; Fatty Acids|*ME
MeSH Heading
Human; Oxidation-Reduction

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0029-6643
Country of Publication
UNITED STATES

Record 44 from database: MEDLINE
Return To Top
Return To Menu Position #40

Title
Carnitine deficiency-induced cardiomyopathy.
Author
Paulson DJ
Address
Department of Physiology, Midwestern University, Downers Grove, Illinois 60515, USA.
Source
Mol Cell Biochem, 1998 Mar, 180:1-2, 33-41
Abstract
The results of clinical and animal studies suggest that a short term period of moderate secondary carnitine deficiency, in and of itself, does not have a major effect on the cardiac contractile function, although substrate oxidation may be altered. However, with longer durations of carnitine deficiency, alterations occur within the heart that may result in impaired contractile performance, particularly at high workloads. At this point, the mechanisms responsible for the cardiac depression are uncertain. We hypothesize that the alterations in substrate metabolism produced by the carnitine deficient state results in inadequate ATP production under high workload conditions which result in impaired cardiac contractile performance. Carnitine deficiency may also induce a number of changes in gene expression of key enzymes required for normal cardiac contractile function and metabolism.
Language of Publication
English
Unique Identifier
98206705

Return To Top
Return To Menu Position #40


MeSH Heading (Major)
Carnitine|*DF; Myocardial Diseases|*ET; Vitamin B Deficiency|*CO
MeSH Heading
Animal; Disease Models, Animal; Human; Kinetics; Models, Biological; Support, U.S. Gov't, P.H.S.

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0300-8177
Country of Publication
NETHERLANDS

Record 45 from database: MEDLINE
Return To Top
Return To Menu Position #40

Title
Differential regulation in the heart of mitochondrial carnitine palmitoyltransferase-I muscle and liver isoforms.
Author
Park EA; Cook GA
Address
Department of Pharmacology, College of Medicine, The University of Tennessee, Memphis-The Health Science Center, 38163, USA.
Source
Mol Cell Biochem, 1998 Mar, 180:1-2, 27-32
Abstract
Carnitine palmitoyltransferase-I (CPT-I) plays a crucial role in regulating cardiac fatty acid oxidation which provides the primary source of energy for cardiac muscle contraction. CPT-I catalyzes the transfer of long chain fatty acids into mitochondria and is recognized as the primary rate controlling step in fatty acid oxidation. Molecular cloning techniques have demonstrated that two CPT-I isoforms exist as genes encoding the 'muscle' and 'liver' enzymes. Regulation of fatty acid oxidation rates depends on both short-term regulation of enzyme activity and long-term regulation of enzyme synthesis. Most early investigations into metabolic control of fatty acid oxidation at the CPT-I step concentrated on the hepatic enzyme which can be inhibited by malonyl-CoA and can undergo dramatic amplification or reduction of its sensitivity to inhibition by malonyl-CoA. The muscle CPT-I is inherently more sensitive to malonyl-CoA inhibition but has not been found to undergo any alteration of its sensitivity. Short-term control of activity of muscle CPT-I is apparently regulated by malonyl-CoA concentration in response to fuel supply (glucose, lactate, pyruvate and ketone bodies). The liver isoform is the only CPT-I enzyme present in the mitochondria of liver, kidney, brain and most other tissues while muscle CPT-I is the sole isoform expressed in skeletal muscle as well as white and brown adipocytes. The heart is unique in that it contains both muscle and liver isoforms. Liver CPT-I is highly expressed in the fetal heart, but at birth its activity begins to decline whereas the muscle isoform, which is very low at birth, becomes the predominant enzyme during postnatal development. In this paper, the differential regulation of the two CPT-I isoforms at the protein and the gene level will be discussed.
Language of Publication
English
Unique Identifier
98206704

Return To Top
Return To Menu Position #40


MeSH Heading (Major)
Carnitine O-Palmitoyltransferase|GE/*ME; Isoenzymes|*ME; Liver|*EN; Mitochondria, Heart|*EN; Muscles|*EN
MeSH Heading
Amino Acid Sequence; Animal; Gene Expression Regulation, Developmental; Gene Expression Regulation, Enzymologic; Human; Molecular Sequence Data

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0300-8177
Country of Publication
NETHERLANDS

Record 46 from database: MEDLINE
Return To Top
Return To Menu Position #40

Title
Propionyl-L-carnitine.
Author
Wiseman LR; Brogden RN
Address
Adis International Limited, Auckland, New Zealand.
Source
Drugs Aging, 1998 Mar, 12:3, 243-8; discussion 249-50
Abstract
Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activity. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. Improvements in maximum walking distance (MWD) correlated positively with increased mitochondrial oxidative adenosine triphosphate (ATP) synthesis in a study in patients with peripheral arterial disease. Oral propionyl-L-carnitine 1 to 3 g/day significantly improved mean MWD compared with placebo in patients with peripheral arterial obstructive disease (Fontaine Leriche stage II) in double-blind multicentre phase III studies (mean improvements ranged from 21 to 50% with placebo and from 33 to 73% with propionyl-L-carnitine). In one phase III study, propionyl-L-carnitine 1 to 3 g/day significantly improved mean MWD (measured by treadmill) compared with placebo (by 73 vs 46% after 24 weeks) in patients with intermittent claudication. Oral propionyl-L-carnitine therapy was associated with significant improvements in quality of life compared with placebo in patients with a baseline MWD < 250m. Propionyl-L-carnitine appears to be well tolerated, showing a similar incidence of adverse events to that reported in placebo recipients.
Language of Publication
English
Unique Identifier
98195507

Return To Top
Return To Menu Position #40


MeSH Heading (Major)
Arterial Occlusive Diseases|*DT; Cardiotonic Agents|PK/*TU; Carnitine|*AA/PK/TU
MeSH Heading
Aged; Clinical Trials; Human; Muscle, Skeletal|DE/ME

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
1170-229X
Country of Publication
NEW ZEALAND

Record 47 from database: MEDLINE
Return To Top
Return To Menu Position #40

Title
Carnitine metabolism during exercise.
Author
Brass EP; Hiatt WR
Address
Department of Medicine, Case Western Reserve University, Cleveland, Ohio 44106-4981.
Source
Life Sci, 1994, 54:19, 1383-93
Abstract
Carnitine is an important cofactor for normal cellular metabolism. Optimal utilization of fuel substrates for ATP generation by skeletal muscle during exercise is dependent on adequate carnitine stores. During short periods of exercise the skeletal muscle carnitine pool is largely segregated from extracellular carnitine. In normal human subjects, only minimal changes in the muscle carnitine pool are observed during exercise at work loads below the lactate threshold. In contrast, at work-loads above the lactate threshold the muscle total carnitine is redistributed from carnitine to acetylcarnitine, with the acetylcarnitine content correlated with the muscle acetyl-CoA and lactate contents. In contrast, in patients with peripheral arterial disease, an accumulation of acylcarnitines is observed at all work loads. Patients with chronic renal failure who are on hemodialysis demonstrate a poor exercise capability which is correlated with a decrease in muscle carnitine content. Carnitine supplementation has been shown to improve exercise tolerance in both peripheral arterial disease and hemodialysis patients. Further work is needed to define the mechanism by which exogenous carnitine improves exercise performance in order to better define potential patient populations for therapy and to facilitate optimal dosing regimens.
Language of Publication
English
Unique Identifier
94247261

Return To Top
Return To Menu Position #40

MeSH Heading (Major)
Carnitine|*ME/PD; Exercise|*; Exertion|*; Muscles|DE/*ME; Vascular Diseases|*ME
MeSH Heading
Acetyl Coenzyme A|ME; Acetylcarnitine|ME; Adenosine Triphosphate|ME; Human; Lactates|ME; Reference Values; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0024-3205
Country of Publication
ENGLAND

Record 48 from database: MEDLINE
Return To Top
Return To Menu Position #40

Title
L-Carnitine moiety assay: an up-to-date reappraisal covering the commonest methods for various applications.
Author
Marzo A; Curti S
Address
I.P.A.S. S.A., Clinical Pharmacology Department, Ligornetto, Switzerland.
Source
J Chromatogr B Biomed Sci Appl, 1997 Nov, 702:1-2, 1-20
Abstract
L-Carnitine and its esters are typical endogenous substances. Their homeostatic equilibria are effectively controlled by various mechanisms which include rate-limiting enteral absorption, a multicomponent endogenous pool which is regulated acrding to a mammillary metabolism, an asymmetric body distribution and a saturable tubular reabsorption process leading to renal thresholds. In formal pharmacokinetic and metabolic investigations, the whole L-carnitine pool should be investigated, owing to the rapid interchange process between the various components of the pool. Free L-carnitine, as well as its acyl esters, must therefore be considered from an analytical viewpoint. L-Carnitine, acetyl-L-carnitine and total L-carnitine (the latter as an expression of the whole pool) can easily be assayed by enzyme or radioenzyme methods. Propionyl-L-carnitine and other esters containing fatty acids with more than three carbon atoms can be assayed using various HPLC approaches. Tandem mass spectrometry is another excellent approach to the assay of carnitine and its short-chain, medium-chain and long-chain esters. As L-carnitine contains a chiral carbon atom, the enantioselectivity of the assays is also considered in this review. Metabolites produced by enteral bacteria, namely tri-, di- and mono-methylamine, gamma-butyrobetaine, along with other systemic metabolites, namely trimethylamine N-oxide and N-nitroso dimethylamine, are very important in quantitative and toxicokinetic terms and require specific assay methods. This review covers the commonest methods of assaying carnitine and its esters, their impurities and pre-systemic and systemic metabolites and gives analytical details and information on their applications in pharmaceutics, biochemistry, pharmacokinetics and toxicokinetics.
Language of Publication
English
Unique Identifier
98109605

Return To Top
Return To Menu Position #40


MeSH Heading (Major)
Carnitine|*AN/CH/ME; Chromatography, Gas|*MT; Chromatography, High Pressure Liquid|*MT; Spectrum Analysis, Mass|*MT
MeSH Heading
Child, Preschool; Comparative Study; Esters; Female; Human

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
1387-2273
Country of Publication
NETHERLANDS

Record 49 from database: MEDLINE
Return To Top
Return To Menu Position #40

Title
Acetyl-L-carnitine and Alzheimer's disease: pharmacological considerations beyond the cholinergic sphere.
Author
Carta A; Calvani M; Bravi D; Bhuachalla SN
Address
Sigma-Tau Pharmaceuticals, Department of Scientific Affairs, Gaithersburg, Maryland 20878.
Source
Ann N Y Acad Sci, 1993 Sep, 695:, 324-6
Abstract
Since ALCAR and L-carnitine are "shuttles" of long chain fatty acids between the cytosol and the mitochondria to undergo beta-oxidation, they play an essential role in energy production and in clearing toxic accumulations of fatty acids in the mitochondria. ALCAR has been considered of potential use in senile dementia of the Alzheimer type (SDAT) because of its ability to serve as a precursor for acetylcholine. However, pharmacological studies with ALCAR in animals have demonstrated its facility to maximize energy production and promote cellular membrane stability, particularly its ability to restore membranal changes that are age-related. Since recent investigations have implicated abnormal energy processing leading to cell death, and severity-dependent membrane disruption in the pathology of Alzheimer's disease, we speculate that the beneficial effects associated with ALCAR administration in Alzheimer patients are due not only to its cholinergic properties, but also to its ability to support physiological cellular functioning at the mitochondrial level. This hypothetical mechanism of action is discussed with respect to compelling supportive animal studies and recent observations of significant decrease of carnitine acetyltransferase (the catalyst of L-carnitine acylation to acetyl-L-carnitine) in autopsied Alzheimer brains.
Language of Publication
English
Unique Identifier
94057854

Return To Top
Return To Menu Position #40


MeSH Heading (Major)
Acetylcarnitine|PD/*TU; Alzheimer Disease|*DT/EN/PA
MeSH Heading
Aging|ME; Animal; Brain|EN/PA; Carnitine O-Acetyltransferase|ME; Human; Mitochondria|DE/ME; Support, Non-U.S. Gov't; Transcription, Genetic|DE

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0077-8923
Country of Publication
UNITED STATES

Record 50 from database: MEDLINE
Return To Top
Return To Menu Position #40

Title
Regulation of the long-chain carnitine acyltransferases.
Author
Brady PS; Ramsay RR; Brady LJ
Address
Department of Food Science and Nutrition, University of Minnesota, St. Paul 55108.
Source
FASEB J, 1993 Aug, 7:11, 1039-44
Abstract
Long-chain carnitine acyltransferases are a family of enzymes found in mitochondria, peroxisomes, and endoplasmic reticulum that catalyze the exchange of carnitine for coenzyme A in the fatty acyl-CoA. Conversion of the fatty acyl-CoA to fatty acylcarnitine renders the fatty acid more permeable to the various cellular membranes. The mitochondrial carnitine palmitoyltransferases are considered important in the regulation of mitochondrial beta-oxidation of long-chain fatty acids. However, palmitoylcarnitine produced by peroxisomal carnitine octanoyltransferase or by microsomal carnitine palmitoyltransferase is not different from that produced by the mitochondrial enzyme. Therefore, for there to be control of fatty acid oxidation by the long-chain carnitine acyltransferases, there would have to be some mechanism to coordinately regulate these varied enzymes. The first system of regulation involves inhibition by malonyl-CoA, an intermediate in the synthesis of fatty acids. Malonyl-CoA inhibits long-chain carnitine acyltransferase activity by all three enzymes at similar concentrations in the physiological range. In addition, the mitochondrial and peroxisomal enzymes are known to be regulated at the level of mRNA transcription by a number of shared factors. Although the microsomal enzyme is less well studied, there does, indeed, appear to be a pattern of coordinate regulation for this system.
Language of Publication
English
Unique Identifier
93380589

Return To Top
Return To Menu Position #40


MeSH Heading (Major)
Carnitine Acyltransferases|*PH
MeSH Heading
Animal; Carnitine O-Palmitoyltransferase|PH; Fatty Acids|ME; Human; Malonyl Coenzyme A|PH; Mitochondria|EN; Support, Non-U.S. Gov't; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.

Publication Type
JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
ISSN
0892-6638
Country of Publication
UNITED STATES

 


Special Pages On The Various of Web Sites Authored by Karl Loren
OC History Oral Chelation Testimonials
Family Of Three Oral Chelation Formulas Life Glow Basic Life Glow Basic Ingredient List
Life Glow Plus Life Glow Plus
Ingredient List
American Heart Association -- Lies
Super Life Glow Super Life Glow
 Ingredient List
FAQ
All Products Shopping Cart Order Section Research
Taheebo Life Tea Witch Doctors Versus Harvard MSM Sulfur
Calcium How Bones Grow Colloidal Minerals
Jean Ross Philosophy The Wednesday Letter
Arthritis & James Coburn's Use Of MSM Karl Loren Viewpoints News And Announcements
Dr. Flanagan's Microhydrin 500 Page Book On Heart Disease Colostrum & Transfer Factor
Germanium Ultrasound Technology Bulk MSM
Cancer & Biopsy Diabetes Heart Disease & Bypass Surgery
Karl Loren's Diet Guarantee Navigation Help Page
The Links Below Jump To Pages On Whatever Web You Are In
Table Of Contents Search This Web Navigation Help Page
Write To Karl Loren -- He Pledges To Answer EVERY Personal Message, Personally.  Click here or on his name in the box below.
The Links Below Are To Various Web Sites Published By Karl Loren
Karl Loren Web Vibrant Life Web Karl Loren's Book
Super Colostrum Bulk MSM Heart Disease
Emmessar Happiness Arthritis
Instead Of Chelation Therapy Super Colostrum (2)
Immune Egg Central Page For All Web Sites!
 

I promise to answer your message -- click here to send me a personal message

Dear Karl,                                        

 

 

 

 

SUBSCRIBE:  The Wednesday Letter is a free electronic monthly newsletter written and published by Karl Loren.  You can view more than 50 back issues of this publication by clicking here.  The Wednesday Letter subscription list is maintained on a secure server, no name is ever given or sold to anyone, and it is never used except for this Newsletter.  It is automatically published on the Tuesday night just before the first Wednesday of every month.  You can subscribe to this free monthly electronic letter by entering your eMail address and name below.  You will then automatically receive a request for confirmation, sent to whatever address you have entered.  If you do NOT receive this confirmation request, then you will not be subscribed.  There may have been an error with your address and you should resubmit.  The letter is never sent twice to the same address -- so you do not have to worry about a duplicate subscription.  When you receive this confirmation request you must reply to it, or your subscription will not become active.  No one can subscribe your name, and address, without you being notified, and if you get an unwanted notice of subscription you only need to DO NOTHING and the subscription will NOT be active.

E-Mail Address:
First Name:
Last Name:

REMOVAL:  You can remove yourself from the subscription list in several different ways.  Click here to read about this entire newsletter system.  Every edition of The Wednesday Letter is delivered to your address with YOUR name and address in view on the letter, with a link that allows you to remove THAT name from the subscription list.  If you try to send this removal message from an address different from the one you used to send in your original confirmation, then you will get a warning notice first, sent to the subscription address, asking you to confirm that you want to be removed from the list -- by replying to THAT request for confirmation, you will then be automatically removed.  Thus, no one else can unsubscribe you, from some other computer, without your knowledge.  But, if you send in the unsubscribe notice from the same machine used to receive the Letter, then the removal from the subscription list is automatic.

E-Mail Address:

Personal Message:  When you send a personal message to Karl Loren, you will receive a personal reply as per his instructions.  Karl pledges that every personal message will get a personal answer. When you provide your mail address, we will send you free information including our free catalog and a cassette tape lecture by Karl Loren about heart disease, no charge, by mail, even if outside the US.  You can select particular information you would like to receive, along with the free cassette tape and catalog.

You can reach Vibrant Life in many ways, including by mail to Vibrant Life, 2808 N. Naomi St., Burbank, CA 91504.  Within the US and Canada, use the toll free number:  (800) 523-4521, the local number:  (818) 558-1799, the FAX:  (818) 558-7299, eMail to kimberly@oralchelation.com or any one of the hundreds of message forms throughout the 50 web sites.  Vibrant Life normally ships the same day we get an order.  There are message forms on each of the 100,000+ pages on this and other sites where you can communicate with Vibrant Life.  Check out our companion site, at:  http://www.oralchelation.net where Karl's 2000 page book is published.  Karl Loren is the author and webmaster for this BOOK, as well as for another web site about ORAL CHELATION.  His personal philosophical articles are at PHILOSOPHY

Copyright © May 20, 2008 6:24 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED.  Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions:  One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site.  This permission does not extend to materials on this site which are copyrighted by others.